Jan 11, 2021
Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, today announced that its CEO, Natalia Perekhvatova, is presenting at the 13th Annual Biotech Showcase Digital 2021 Conference this week. The conference is virtual and is occurring in parallel with the J.P. Morgan 39th Annual Healthcare Conference 2021.
“We are pleased to have the opportunity to update the many attendees of Biotech Showcase and present the significant advances in our clinical programs in ophthalmology,” said Natalia Perekhvatova.
About Mitotech S.A.
Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria targeting cardiolipin peroxidation inhibitors. Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases. In VISTA-1 – a Phase 2b/3 clinical study in the United States (NCT03764735) - SkQ1 showed evidence of efficacy in reducing both the signs and symptoms in Dry Eye subjects. Results of a Phase 3 study in Dry Eye (VISTA-2) are expected in Q1 2021. Glaucoma, Dry AMD and LHON programs for SkQ1 ophthalmic solution are at pre-Phase 2 stage with Phase 2 studies projected to start in 2021.